426 related articles for article (PubMed ID: 34827170)
1. Siglecs as Therapeutic Targets in Cancer.
Lim J; Sari-Ak D; Bagga T
Biology (Basel); 2021 Nov; 10(11):. PubMed ID: 34827170
[TBL] [Abstract][Full Text] [Related]
2. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
3. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
4. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
5. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.
Feng H; Feng J; Han X; Ying Y; Lou W; Liu L; Zhang L
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254780
[TBL] [Abstract][Full Text] [Related]
6. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
7. Steering Siglec-Sialic Acid Interactions on Living Cells using Bioorthogonal Chemistry.
Büll C; Heise T; van Hilten N; Pijnenborg JF; Bloemendal VR; Gerrits L; Kers-Rebel ED; Ritschel T; den Brok MH; Adema GJ; Boltje TJ
Angew Chem Int Ed Engl; 2017 Mar; 56(12):3309-3313. PubMed ID: 28194834
[TBL] [Abstract][Full Text] [Related]
8. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
Mitic N; Milutinovic B; Jankovic M
Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
[TBL] [Abstract][Full Text] [Related]
9. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
10. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.
Lübbers J; Rodríguez E; van Kooyk Y
Front Immunol; 2018; 9():2807. PubMed ID: 30581432
[TBL] [Abstract][Full Text] [Related]
12. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.
Chan C; Lustig M; Jansen JHM; Garcia Villagrasa L; Raymakers L; Daamen LA; Valerius T; van Tetering G; Leusen JHW
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444515
[TBL] [Abstract][Full Text] [Related]
13. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
14. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
15. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
16. Leishmania donovani Utilize Sialic Acids for Binding and Phagocytosis in the Macrophages through Selective Utilization of Siglecs and Impair the Innate Immune Arm.
Roy S; Mandal C
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004904. PubMed ID: 27494323
[TBL] [Abstract][Full Text] [Related]
17. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
Gianchecchi E; Arena A; Fierabracci A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
[TBL] [Abstract][Full Text] [Related]
18. Flow Cytometry-Based Detection of Siglec Ligands.
Schmidt EN; Jung J; Macauley MS
Methods Mol Biol; 2023; 2657():181-193. PubMed ID: 37149531
[TBL] [Abstract][Full Text] [Related]
19. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
Meyer SJ; Linder AT; Brandl C; Nitschke L
Front Immunol; 2018; 9():2820. PubMed ID: 30559744
[TBL] [Abstract][Full Text] [Related]
20. Discovery, classification, evolution and diversity of Siglecs.
Angata T; Varki A
Mol Aspects Med; 2023 Apr; 90():101117. PubMed ID: 35989204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]